navitoclax

Term ID

CHEBI:131174

Synonyms

• 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
• A-855071.0
• ABT 263
• ABT-263
• ABT263
• navitoclax
• navitoclaxum

Definition

A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies.

References

• CAS:923564-51-6
• Chemspider:21864722
• DrugBank:DB12340
• KEGG:D09935
• LINCS:LSM-42776
• LINCS:LSM-4738
• PDBeChem:1XJ
• PMCID:PMC6011937
• PMID:18085673
• PMID:23291630
• PMID:26575826
• PMID:26958630
• PMID:28713162
• PMID:28947240
• PMID:29156797
• PMID:29237758
• PMID:29580266
• PMID:29753379
• PMID:29913235
• PMID:30224339
• PMID:30614795
• PMID:30721730
• PMID:30919222
• PMID:31276572
• PMID:31367332
• PMID:31399555
• PMID:31459977
• PMID:32247610
• PMID:32337074
• PMID:32446890
• PMID:32509782
• PMID:32611834
• PMID:32652830
• PMID:32675749
• PMID:32687646
• Wikipedia:Navitoclax

Ontology

ChEBI  ( EBI )